The ubiquitin-proteasome proteolysis pathway: Potential target for disease intervention

Journal of Parenteral and Enteral Nutrition

Volumn 28, Issue 4, 2004, Pages 272-277

  Breen, Heather B ^a   Espat, N Joseph ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

3 METHYLHISTIDINE; ADENOSINE TRIPHOSPHATE; AMINOPEPTIDASE; BORTEZOMIB; CHYMOTRYPSIN; CISPLATIN; GEMCITABINE; I KAPPA B; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; MESSENGER RNA; PACLITAXEL; PEPTIDASE; POLYUBIQUITIN; PROTEASOME; PROTEASOME INHIBITOR; PROTEIN C JUN; PROTEIN FOS; PROTEIN P21; PROTEIN P53; REACTIVE OXYGEN METABOLITE; UBIQUITIN; UBIQUITIN PROTEIN LIGASE;

ACUTE PHASE RESPONSE; ANOREXIA; CACHEXIA; CANCER PATIENT; CARBOHYDRATE METABOLISM; CLINICAL TRIAL; CONJUGATION; HUMAN; LIPID METABOLISM; METABOLIC RATE; MUSCLE ATROPHY; MYELOMA; NONHUMAN; NUTRITION; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FOLDING; REVIEW; SEPSIS; STARVATION;

EID: 3042643763     PISSN: 01486071     EISSN: None     Source Type: Journal    
DOI: 10.1177/0148607104028004272     Document Type: Review

References (99)

1. Nalepa G, Harper JW. Therapeutic anti-cancer targets upstream of the proteasome. Cancer Treat Rev. 2003;29:49-57.
2. Adams J. The proteasome: structure, function, and role in the cell. Cancer Treat Rev. 2003;29S:3-9.
3. Tanaka K. Molecular biology of proteasomes. Mol Biol Rep. 1995;21:21-26.
4. Hampton RY. ER-associated degradation in protein quality control and cellular regulation. Curr Opin Cell Biol. 2002;14:476-482.
5. Yoshida Y. A novel role for N-glycans in the ERAD system. J Biochem (Tokyo). 2003;134:1183-190.
6. Ellgaard L, Helenius A. Quality control in the endoplasmic reticulum. Nat Rev Mol Cell Biol. 2003;4:181-191.
7. Orlowski M, Wilk S. Ubiquitin-independent proteolytic functions of the proteasome. Arch Biochem Biophys. 2003;415:1-5.
8. Adams J. Proteasome inhibitors as the new anticancer drugs. Curr Opin Oncol. 2002;14:628-634.
9. Hasselgren PO, Wray C, Mammen J. Molecular regulation of muscle cachexia: it may be more than the proteasome. Biochem Biophys Res Commun. 2002;290:1-10.
10. th ed. Baltimore, MD: Williams & Wilkins; 1999:963-986.
11. Wing SS, Banville D. 14-kDa ubiquitin-conjugating enzyme: structure of the rat gene and regulation upon fasting and by insulin. Am J Physiol. 1994;267:E39-E48.
12. Medina R, Wing SS, Goldberg AL. Increase in levels of polyubiquitin and proteasome mRNA in skeletal muscle during starvation and denervation atrophy. Biochem J. 1995;307:631-637.
13. Wing SS, Haas AL, Goldberg AL. Increase in ubiquitin-protein conjugates concomitant with the increase in proteolysis in rat skeletal muscle during starvation and atrophy denervation. Biochem J. 1995;307:639-645.
14. Ortiz RM, Wade CE, Ortiz CL. Effects of prolonged fasting on plasma cortisol and TH in postweaned northern elephant seal pups. Am J Physiol Regul Integr Comp Physiol. 2001;280:R790-R795.
15. Makino S, Kaneda T, Nishiyama M, Asaba K, Hashimoto K. Lack of decrease in hypothalamic and hippocampal glucocorticoid receptor mRNA during starvation. Neuroendocrinology. 2001;74:120-128.
16. Nazarloo HP, Nishiyama M, Tanaka Y, Asaba K, Hashimoto K. Down-regulation of corticotropin releasing hormone receptor type 2B mRNA expression in the rat cardiovascular system following food deprivation. Regul Pept. 2002;105:121-129.
17. Ahima RS, Prabakaran D, Mantzoros C, et al. Role of leptin in the neuroendocrine response to fasting. Nature. 1996;382:250-252.
18. Friedl KE, Moore RJ, Hoyt RW, Marchitelli LJ, Martinez-Lopez LE, Askew EW. Endocrine markers of semistarvation in healthy lean men in a multistressor environment. J Appl Physiol. 2000;88:1820-1830.
19. Chan JL, Heist K, DePaoli AM, Veldhuis JD, Mantzoros CS. The role of falling leptin levels in the neuroendocrine and metabolic adaptation to short-term starvation in healthy men. J Clin Invest. 2003;111:1409-1421.
20. Vance ML, Thorner MO. Fasting alters pulsatile and phythmic cortisol release in normal man. J Clin Endocrinol Metab. 1989;68:1013-1018.
21. El-Migdadi F, El-Akawi Z, Abudheese R, Bashir N. Plasma levels of adrenocorticotropic hormone and cortisol in people living in an environment below sea level (Jordan Valley) during fasting in the month of Ramadan. Horm Res. 2002;58:279-282.
22. Du J, Mitch WE, Wang X, Price SR. Glucocorticoids induce proteasome C3 subunit expression in L6 muscle cells by opposing the suppression of its transcription by NFκB. J Biol Chem. 2000;275:19661-19666.
23. Wing SS, Goldberg AL. Glucocorticoids activate the ATP-ubiquitin- dependent proteolytic system in skeletal muscle during fasting. Am J Physiol. 1993;264:E668-E676.
24. Li WQ, Wang XY, Zhu H, et al. [Albumin kinetics in patients with severe sepsis] [in Chinese]. Zhonghua Wai Ke Za Zhi 2003;6:423-426.
25. Van Way CW. Nutritional support in injured patient. Surg Clin North Am. 1991;71:537.
26. Ruot B, Papet I, Bechereau F, et al. Increased albumin plasma efflux contributes to hypoalbuminemia only during early phase of sepsis in rats. Am J Physiol Regul Integr Comp Physiol. 2003;284:R707-R713.
27. Helton WS, Espat NJ. Defining mechanisms of omega-3 fatty-acid activity. Nutrition. 2001;17:674.
28. O'Leary MJ, Koll M, Ferguson CN, et al. Liver albumin synthesis in sepsis in the rat: influence of parenteral nutrition, glutamine and growth hormone. Clin Sci E-Pub. Jul 23, 2003.
29. Kotler DP. Cachexia. Ann Intern Med. 2000;133:622-634.
30. Tiao G, Fagan JM, Samuels N, et al. Sepsis stimulates nonlysosomal, energy-dependent proteolysis and increases ubiquitin mRNA levels in rat skeletal muscle. J Clin Invest. 1994;94:2255-2264.
31. Chai J, Wu Y, Sheng ZZ. Role of ubiquitin-proteasome pathway in skeletal muscle wasting in rats with endotoxemia. Crit Care Med. 2003;31:1802-1807.
32. Hobler SC, Tiao G, Fischer JE, Monaco J, Hasselgren PO. Sepsis-induced increase in muscle proteolysis is blocked by specific proteasome inhibitors. Am J Physiol. 1998;274:R30-R37.
33. Homma S, Horsch A, Pouch MN, Petit F, Briand Y, Schmid HP. Proteasomes (prosomes) inhibit the translation of tobacco mosaic virus RNA by preventing the formation of inhibition complexes. Mol Biol Rep. 1994;20:57-61.
34. Horsch A, Martins de Sa C, Dineva B, Spindler E, Schmid HP. Prosomes discriminate between mRNA of adenovirus infected and uninfected HeLa cells. FEBS Lett. 1989;246:131-136.
35. Qureshi N, Perera P-Y, Shen J, et al. The proteasome as a lipopolysaccharide-binding protein in macrophages: differential effects of proteasome inhibition on lipopolysaccharide-induced signaling events. J Immunol. 2003;171:1515-1525.
36. Espat NJ, Moldawer LL, Copeland EM. Cytokine-mediated alterations in host metabolism prevent nutritional repletion in cachectic cancer patients. J Surg Oncol. 1995;58:77-82.
37. Von Haehling S, Genth-Zotz S, Anker SD, Volk HD. Cachexia: a therapeutic approach beyond cytokine antagonism. Int J Cardiol. 2002;85:173-183.
38. Andreyev HJN, Norman AR, Oates J, et al. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies? Eur J Cancer. 1998;35:503-509.
39. Bistrian BR, Blackburn GL, Scrimshaw NS, Flatt JP. Cellular immunity in semistarved states in hospitalized adults. Am J Clin Nutr. 1978;28:1148-1153.
40. Fearon KCH. The mechanisms and treatment of weight loss in cancer. Proc Nutr Soc. 1992;51:251-265.
41. Nixon DW, Heymsefield SB, Cohen AE. Protein calorie under-nutrition in hospitalized cancer patients. Am J Med. 1980;68:683-690.
42. Wigmore SJ, Plester CE, Richardson RA, Fearon KC. Changes in nutritional status associated with unresectable pancreatic cancer. Br J Cancer. 1997;75:106-109.
43. Mitch ME, Goldberg AL. Mechanisms of muscle wasting: the role of the ubiquitin proteasome pathway. N Engl J Med. 1996;335:1897-1905.
44. Todorov P, Cariuk P, McDevitt T, Coles B, Fearon K, Tisdale M. Characterization of a cancer cachectic factor. Nature. 1996;379:739-742.
45. Smith KL, Tisdale MJ. Mechanism of muscle protein degradation in cancer cachexia. Br J Cancer. 1993;68:314-318.
46. Smith HJ, Lorite MJ, Tisdale MJ. Effect of a cancer cachectic factor on protein synthesis/degradation by a tumour factor. Cancer Res. 1999;59:5507-5513.
47. Lorite MJ, Smith HJ, Arnold JA, Morris A, Thompson MG, Tisdale MJ. Activation of ubiquitin-dependent proteolysis in skeletal muscle in vivo and murine myoblasts in vitro by a proteolysis-inducing factor (PIF). Br J Cancer. 2001;85:297-302.
48. Lorite MJ, Cariuk P, Tisdale MJ. Induction of muscle protein degradation by a tumour factor. Br J Cancer. 1997;76:1035-1040.
49. Williams A, Sun X, Fischer JE, Hasselgren P-O. The expression of genes in the ubiquitin-proteasome proteolytic pathway is increased in skeletal muscle from patients with cancer. Surgery 1999;126:744-750.
50. Lorite MJ, Thompson MG, Drake JL, Carling G, Tisdale MJ. Mechanism of muscle protein degradation induced by a cancer cachectic factor. Br J Cancer. 1998;78:850-856.
51. Whitehouse AS, Smith HJ, Drake JL, Tisdale MJ. Mechanism of attenuation of skeletal muscle protein catabolism in cancer cachexia by eicosapentaenoic acid. Cancer Res. 2001;61:3604-3609.
52. Smith HJ, Tisdale MJ. Induction of apoptosis by a cachectic-factor in murine myotubes and inhibition by eicosapentaenoic acid. Apoptosis. 2003;8:161-169.
53. Barber MD. Cancer cachexia and its treatment with fish-oil-enriched nutritional supplementation. Nutrition. 2001;17:751-755.
54. rd ed. St. Louis, Mo: Mosby; 1997.
55. Cerami A, Ikeda Y, Le Trang N, Hotez PJ, Beutler B. Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor). Immunol Lett. 1985;11:173-177.
56. Espat NJ, Copeland EM, Moldawer LL. Tumor necrosis factor and cachexia: a current perspective. Surg Oncol. 1994;3:255-262.
57. Ebisui C, Tsujinaka T, Morimoto T, et al. Interleukin-6 induces proteolysis by activating intracellular proteases (cathepsins B and L, proteasome) in C2C12 myotubes. Clin Sci. 1995;89:431-439.
58. Llovera M, Carbo N, Lopez-Sorian J, et al. Different cytokines modulate ubiquitin gene expression in rat skeletal muscle. Cancer Lett. 1998;133:83-87.
59. Zamir O, Hasselgren PO, Kunkel SL, Frederick J, Higashiguchi T, Fischer JE. Evidence that tumor necrosis factor participates in the regulation of muscle proteolysis during sepsis. Arch Surg. 1992;127:170-174.
60. Charters Y, Grimble RF. Effect of recombinant human tumour necrosis factor alpha on protein synthesis in liver, skeletal muscle, and skin of rats. Biochem J. 1989;258:493-497.
61. Zamir O, Hasselgren PO, James H, Higashiguchi T, Fischer JE. Effect of tumor necrosis factor or interleukin-1 on muscle amino acid uptake and the role of glucocorticoids. Surg Gynecol Obstet. 1993;177:27-32.
62. Hall-Angeras M, Angeras U, Zamir O, Hasselgren PO, Fischer JE. Interaction between corticosterone and tumor necrosis factor stimulated protein breakdown in rat skeletal muscle, similar to sepsis. Surgery. 1990;108:460-466.
63. Tiao G, Fagan J, Roegner V, et al. Energy-ubiquitin-dependent muscle proteolysis during sepsis in rats regulated by glucocorticoids. J Clin Invest. 1996;97:339-348.
64. Hall-Angeras M, Angeras U, Zamir O, Hasselgren PO, Fischer JE. Effect of the glucocorticoid receptor antagonist RU 38486 on muscle protein breakdown in sepsis. Surgery. 1991;109:468-473.
65. Imajoh-Ohmi S, Kawaguchi T, Sugiyama S, Tanaka K, Omura S, Kikuchi H. Lactacystin, a specific inhibitor of the proteasome, induces apoptosis in human monoblast U937 cells. Biochem Biophys Res Commun. 1995;217:1070-1077.
66. Almond JB, Snowden RT, Hunter A, Dinsdale D, Cain K, Cohen GM. Proteasome inhibitor-induced apoptosis of B-chronic lymphocytic leukaemia cells involves cytochrome c release and caspase activation, accompanied by formation of an ∼700 kDA Apaf-1 containing apoptosome complex. Leukemia. 2001;15:1388-1397.
67. McDade TP, Perugini RA, Fittimberga Jr FJ, Callery MP. Ubiquitin-proteasome inhibition enhances apoptosis of human pancreatic cancer cells. Surgery. 1999;126:371-377.
68. Adams J, Behnke M, Chen S, et al. Potent and selective inhibitors of the proteasome: dipeptidyl boronic acids. Bioorg Med Chem Lett. 1998;8:333-338.
69. Lightcap ES, McCormack TA, Pien CS, Chau V, Adams J, Elliott PJ. Proteasome inhibition measurements: clinical applications. Clin Chem. 46:673-683.
70. Adams J, Elliott PJ. New agents in cancer clinical trials. Oncogene. 2000;19:6687-6692.
71. Hamilton AL, Eder JP, Pavlick A, et al. Proceedings of the American Society of Clinical Oncology, May 12-15, San Francisco, CA, abstract 336. American Society of Clinical Oncology, Alexandria, VA, 2001.
72. Papandreou CN, Daliani D, Millikan RE, et al. Proceedings of the American Society of Clinical Oncology, May 12-15, San Francisco, CA, abstract 340. American Society of Clinical Oncology, Alexandria, VA, 2001.
73. Aghajanian C, Soignet S, Dizon D, et al. Proceedings of the American Society of Clinical Oncology, May 12-15, San Francisco, CA, abstract 338. American Society of Clinical Oncology, Alexandria, VA, 2001.
74. Erlichman C, Adjei AA, Thomas JP, et al. Proceedings of the American Society of Clinical Oncology, May 12-15, San Francisco, CA, abstract 337. American Society of Clinical Oncology, Alexandria, VA, 2001.
75. Richardson P, Barlogie B, Berenson J, et al. Proceedings of the American Society of Hematology, December 6-10, Philadelphia, abstract 385. American Society of Hematology, Washington, DC, 2002.
76. O'Connor O, Moskowitz C, Wright JJ, et al. Proceedings of the American Society of Hematology, December 6-10, Philadelphia, abstract 3063. American Society of Hematology, Washington, DC, 2002.
77. Evan GI, Vousden KH. Proliferation, cell cycle and apoptosis in cancer. Nature. 2001;411:342-348.
78. Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998;281:1309-1312.
79. Ling Y, Liebes L, Zou Y, Perez-Soler R. Reactive oxygen species generation mediate mitochondrial dysfunction and subsequent in the apoptotic response to bortezomib, a novel proteasome inhibitor, in human H460 non-small cell lung cancer cells. J Biol Chem. 2003;278:33714-33723.
80. Cusack Jr JC, Liu R, Houston M, et al. Enhanced chemosensitivity to CPT-11 with proteasome inhibitor PS-341: implications for systemic nuclear factor kappa B inhibition. Cancer Res. 2001;61:3535-3540.
81. Hideshima T, Richardson P, Chauhan D, et al. The proteasome inhibitor PS-341 inhibits growth, induces apoptosis, and overcomes drug resistance in human multiple myeloma cells. Cancer Res. 2001;61:3071-3076.
82. Frankel A, Man S, Elliott P, Adams J, Kerbel RS. Lack of multicellular drug resistance observed in human ovarian and prostate carcinoma treated with the proteasome-inhibitor PS341. Clin Cancer Res. 2000;6:3719-3728.
83. Neumeier H, Hoar K, Pink M, Adams J, Kerbel RS. Hypoxia increases potency of the proteasome inhibitor Velcade™ (bortezomib) for injection: potential for a hypoxic cell cytotoxin in solid tumors. Presented at the EORTC-NCI-ACR Conference on Molecular Targets and Cancer Therapeutics, Frankfurt, Germany, November 19-22, 2002.
84. Adams J, Palombella VJ, Sausville EA, et al. Proteasome inhibitors: a novel class of potent and effective antitumor agents. Cancer Res. 1999;59:2615-2622.
85. Russo SM, Tepper JE, Baldwin AS, et al. Enhancement of radiosensitivity by proteasome inhibition: implications for a role of NFKB. Int J Radiat Oncol Biol Phys. 2001;50:183-193.
86. Bold RJ, Virudachalam S, McConkey DJ. Chemosensitization of pancreatic cancer by inhibition of the 26S proteasome. J Surg Res. 2001;100:11-17.
87. Shah SA, Potter MW, McDade TP, et al. 26S proteasome inhibition induces apoptosis and limits growth of human pancreatic cancer. J Cell Biochem. 2001;82:110-122.
88. Harbison MT, Bruns CJ, Bold RJ, et al. Proteasome inhibitor PS-341 is effective in the treatment of human pancreatic carcinoma via the inhibition of NFκB and subsequent inhibition of vascular endothelial growth factor production. Proc Am Assoc Cancer Res. 2000;41:7.
89. An J, Sun YP, Adams J, et al. Drug interactions between the proteasome inhibitor bortezomib and cytotoxic chemotherapy, tumor necrosis factor (TNF) α, and TNF-related apoptosis-inducing ligand in prostate cancer. Clin Cancer Res. 2003;12:4537-4545.
90. Grimm LM, Goldberg AL, Poirier GG, Schwartz LM, Osborne BA. Proteasomes play an essential role in thymocyte apoptosis. EMBO J. 1996;15:3835-3844.
91. Sadoul R, Fernandez PA, Quiquerez AL, et al. Involvement of the proteasome in the programmed cell death of NGF-deprived sympathetic neurons. EMBO J. 1996;15:3845-3852.
92. Kostova Z, Wolf DH. For whom the bell tolls: protein quality control of the endoplasmic reticulum and the ubiquitin-proteasome connection. EMBO J. 2003;22:2309-2317.
93. Chiarugi P. Reactive oxygen species as mediators of cell adhesion. Ital J Biochem. 2003;52:28-32.
94. Kang DH. Oxidative stress, DNA damage, and breast cancer. AACN Clin Issues. 2002;13:540-549.
95. Benhar M, Engelberg D, Levitzki A. ROS, stress-activated kinases and stress signaling in cancer. EMBO Rep. 2002;3:420-425.
96. Hyun D-H, Lee MH, Halliwell B, Jenner P. Proteasomal inhibition causes the formation of protein aggregates containing a wide range of proteins including nitrated proteins. J Neurochem. 2003;86:363-373.
97. 2+-dependent proteolysis in skeletal muscle and heart in cancer cachexia. Br J Cancer. 2001;84:946-950.
98. Hasselgren PO, Wray C, Mammen J. Molecular regulation of muscle cachexia: it may be more than the proteasome. Biochem Biophys Res Comm. 2002;290:1-10.
99. Hasselgren PO, Fischer JE. Muscle cachexia: current concepts of intracellular mechanisms and molecular regulation. Ann Surg. 2001;233:9-17.